Cerevel Therapeutics Advances in Merger Amid FTC Review

Cerevel Therapeutics Holdings (CERE) has released an update.

Cerevel Therapeutics Holdings, Inc. successfully held a special stockholders’ meeting to vote on a merger with AbbVie Inc., receiving overwhelming approval with a high stockholder turnout. Additionally, the company is addressing a request from the FTC for more information, which extends the antitrust review period. Despite this, Cerevel remains optimistic about completing the merger by mid-2024, pending regulatory approval and fulfillment of other conditions.

For further insights into CERE stock, check out TipRanks’ Stock Analysis page.